Patent · US Active

Compositions and methods for treatment of thyroid eye disease

US11548951B1 · kind B1 · utility

2Cited by

4References

12Claims

0Family size

Assignee

Viridian Therapeutics, Inc. · US

Inventors

Vahe Bedian · Framingham, US
Peter Harwin · Waltham, US
Tomas Kiselak · Waltham, US
Angela She · Waltham, US
Jonathan Violin · Waltham, US
Yang Zhao · North Andover, US

Key dates

Filing date	Aug 29, 2022
Grant date	Jan 10, 2023
Priority date	—
Expiry date	Aug 29, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof are provided herein and antibodies and pharmaceutical compositions that can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, including reducing proptosis and Clinical Activity Score (CAS) in said subjects, by inhibiting the activity of IGF-1R with such antibodies and compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.